These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23084808)

  • 1. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.
    Kay J; Feagan BG; Guirguis MS; Keystone EC; Klein AV; Lubiniecki AS; Mould DR; Nyarko KA; Ridgway AA; Trudeau ME; Wang J
    Biologicals; 2012 Nov; 40(6):517-27. PubMed ID: 23084808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsequent Entry Biologics in Canada: Current State of the Science.
    Endrenyi L; Jamali F; Loebenberg R
    J Pharm Pharm Sci; 2015; 18(2):177-83. PubMed ID: 26158283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparing for subsequent entry biologics in dermatology and rheumatology in Canada.
    Papp K; Bourcier M; Ho V; Burke K; Haraoui B
    J Cutan Med Surg; 2013; 17(5):340-6. PubMed ID: 24067855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.
    Grabowski D; Henderson B; Lam D; Keystone EC; Thorne C; Jamal S; Pope J; Haraoui B; Lin D; Revers L
    Clin Rheumatol; 2015 Aug; 34(8):1427-33. PubMed ID: 25586522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of follow-on biologics for treatment of multiple sclerosis.
    Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
    Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory considerations in oncologic biosimilar drug development.
    Macdonald JC; Hartman H; Jacobs IA
    MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of subsequent entry biologics in nephrology practice in Canada.
    Martinusen DJ; Lo C; Marin JG; Tsao NW; Leung M
    Can J Kidney Health Dis; 2014; 1():32. PubMed ID: 25780621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct.
    Lim RR
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: State of Clinical and Regulatory Science.
    Klein AV; Wang J; Feagan BG; Omoto M
    J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.